Not yet recruiting
Autoimmune myositis
Not yet recruitingA study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy
Registered drugNo placebo
A study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy
Registered drugNo placebo
- Disease:Autoimmune myositis
- Substances:CABA-201Cyclophosphamide Monohydrate+1
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:CABA-201
- Sponsor:Cabaletta Bio Inc.




